ID: MRFR/HC/5058-HCR | 90 Pages | Published By Rahul Gotadki on March 2023
Global Atrial Fibrillation Market Overview
Atrial Fibrillation Market Size was valued at USD 1.5 billion in 2022. The atrial fibrillation market industry is projected to grow from USD 1.69 Billion in 2023 to USD 3.59 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.30% during the forecast period (2023 - 2030). Rising prevalence of atrial fibrillation and increasing approval of products are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Atrial Fibrillation Market Trends
The primary causes of cardiovascular diseases, especially atrial fibrillation, are usually high blood pressure and obesity. The Framingham Heart Study found that obesity raised the chance of paroxysmal atrial fibrillation developing to persistent atrial fibrillation by 45% to 50% and that hypertension was linked to 14% of atrial fibrillation risks. Due to socioeconomic factors including dietary and other habits brought on by a person's lifestyle, the prevalence of these diseases is increasing (excessive alcohol consumption and smoking). According to WHO assumptions, 35% of people aged 20 years and over were overweight. Since 1980, the prevalence of obesity has nearly doubled worldwide, and it is predicted to rise quickly in the coming years. In 2008, there were 1 billion people worldwide who had hypertension. According to the WHO, there were 40% of low, middle, and upper middle-income nations and 35% of high-income countries with hypertension prevalence in 2008. The worldwide atrial fibrillation market CAGR is anticipated to grow throughout the forecast period due to the high and rising prevalence of these disorders.
However, from over projected period, rising atrial fibrillation rates are anticipated to fuel the expansion of the worldwide atrial fibrillation market. For instance, data from the Centers for Disease Control and Prevention (CDC) published in July 2022 indicated that more than 454,000 hospitalizations in the United States each year have atrial fibrillation as the major diagnosis. Each year, the disease causes roughly 158,000 deaths in the United States.
Figure 1: Burden of Atrial Fibrillation in Developed and Developing Nations
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Moreover, the combination pharmaceutical therapy is a model and promising atrial fibrillation treatment option. In clinical trials, the combined pharmacological therapy demonstrated positive outcomes and would assist meet the unmet medical needs of patients with atrial fibrillation. The atrial fibrillation market is expected to be driven by this factor globally. Additionally, research on the combined therapy in an animal model revealed positive and effective anti-arrhythmic results. The Boston Atrial Fibrillation Symposium have seen the introduction of the clinical trials intended to evaluate the effectiveness of a combined therapy using Multaq and Ranexa. Around 150 individuals with non-permanent atrial fibrillation and pacemaker implants were enrolled in the HARMONY clinical trial. Preclinical data from this investigation indicate that this combination therapy, especially in terms of safety and efficacy, is well positioned in the existing atrial fibrillation market revenue.
Atrial Fibrillation Market Segment Insights
Atrial Fibrillation Treatment Insights
The atrial fibrillation market segmentation, based on treatment, includes medications, non-surgical procedures, surgical procedures. The surgical procedures atrial fibrillation segment held the majority share in 2022 in the atrial fibrillation market revenue. This is primarily owing to the increased use of cardiac monitoring technology during atrial fibrillation treatment. The number of patients with arrhythmia or a condition with an irregular heartbeat has increased, which has increased demand for cardiac monitors.
Atrial Fibrillation End User Insights
The atrial fibrillation market segmentation, based on end-user, includes hospitals, electrophysiology labs, ambulatory surgical centers. The hospitals segment dominated the market in 2022. This is due to the increasing use of laser and radio frequency ablation technologies also rising investment globally for the development hospital infrastructure by public and private players is anticipated to support the market growth.
Figure 2: Atrial Fibrillation Market, by End-User, 2022 & 2030 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Atrial Fibrillation Regional Insights
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Atrial Fibrillation market accounted for USD 0.68 billion in 2022 and is expected to exhibit a significant CAGR 45.80% growth during the study period. The main factor driving the growth of the atrial fibrillation market is the high adoption of technologically improved devices for atrial fibrillation in North American nations. Moreover, one of the biggest problems facing healthcare systems is the sharp rise in cardiac disorders among the ageing population. As a result, in order to address this issue, numerous new products are authorized and introduced in North American countries, which further fuels the expansion of the atrial fibrillation market.
Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: Atrial Fibrillation MARKET SHARE BY REGION 2022 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe atrial fibrillation market accounts for the second-largest market share due to the enormous patient population, expanding medical tourism, and considerable attention given by international market participants to developing European nations like Germany and the United Kingdom. Further, the Germany atrial fibrillation market held the largest market share, and the United Kingdom atrial fibrillation market was the fastest growing market in the European region
The Asia-Pacific Atrial Fibrillation Market is expected to grow at the fastest CAGR from 2022 to 2030. This is due to government initiatives to support healthcare and strong economic growth. Moreover, the Asia Pacific atrial fibrillation market is anticipated to develop as a result of rising purchasing power, rising consumer awareness of health issues, and improved disease management. Moreover, China atrial fibrillation market held the largest market share, and the India atrial fibrillation market was the fastest growing market in the Asia-Pacific region
Atrial Fibrillation Key Market Players & Competitive Insights
Major market players are spending a lot of money on R&D to increase their product lines, which will help the atrial fibrillation market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the atrial fibrillation industry must offer cost-effective products and services to expand and survive in an increasingly competitive and rising market environment.
One of the primary business strategies adopted by manufacturers in the atrial fibrillation industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, atrial fibrillation industry has provided transparency and reduced disruptions in supply chain. The atrial fibrillation market major player such as Johnson & Johnson Services Inc, Abbott, Medtronic Plc, Boston Scientific Corporation, MicroPort Scientific Corporation, Biotronik SE & Co. KG, Koninklijke Philips N.V., AtriCure Inc., CardioFocus, Osypka AG and others are working to expand the market demand by investing in research and development activities.
Abbott Laboratories is an American Conglomerate which was established in the year 1888 and headquartered in Chicago, Illinois, United States. It works under diverse range of portfolio, ranging from nutritional, diagnostics to pharmaceuticals and vascular products. Wherein the Vascular is the top selling segment, which ranges from coronary to endovascular, vessel closure and heart devices. The company has an employee base of 18000+ over the world and has established its name with a well-maintained goodwill in the market. There are currently 414+ subsidiaries running under its name and serving its customers over the world. For instance, Aug. 2020, TactiFlex PAF IDE ablation catheter is used to treat patients with paroxysmal atrial fibrillation, an irregular heartbeat, according to Abbott Laboratories, a producer of healthcare medical devices and products. For patients with atrial fibrillation (AFib) symptoms that cannot be managed by medication, it has sensors enabled.
Also, CardioFocus, Inc. was established in year 1990 and it headquarters is in Marlborough, Massachusetts. The company is a medical device inventor and producer dedicated to advancing embolization treatment for cardiovascular disorders such as atrial fibrillation (AFib), a most common heart arrhythmia. More than 10,000 patients in the US, Europe, and Japan have been successfully treated with the company's FDA-approved HeartLight Endoscopic Ablation System. A new benchmark for AFib ablation has been set by the revolutionary HeartLight System, which combines direct vision with titratable laser energy. For instance, in May 2020, CardioFocus, Inc. announced that it has obtained the U.S. Food & Drug administration approval for the next-generation HearLight X3 Endoscopic Ablation System. The system can be utilized to treat paroxysmal symptomatic atrial fibrillation that is drug-refractory and recurrent.
Key Companies in the atrial fibrillation market includes
Johnson & Johnson Services Inc.
Abbott
Medtronic Plc
Boston Scientific Corporation
MicroPort Scientific Corporation
Biotronik SE & Co. KG
Koninklijke Philips N.V.
AtriCure Inc.
CardioFocus
Osypka AG, among others
Atrial Fibrillation Industry Developments
Jan. 2022:AliveCor, Inc. and Voluntis, a pioneer in digital medicines and Aptar Pharma firm, has collaborated to advance atrial fibrillation management for cancer patients.
Atrial Fibrillation Market Segmentation
Atrial Fibrillation Type Outlook
Paroxysmal atrial fibrillation
Persistent atrial fibrillation
Permanent atrial fibrillation
Atrial Fibrillation Treatment Outlook
Medications
Non-surgical procedures
Surgical procedures
Atrial Fibrillation End User Outlook
Hospitals
Electrophysiology Labs
Ambulatory Surgical Centers
Atrial Fibrillation Regional Outlook
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Australia
Rest of Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
Report Attribute/Metric | Details |
Market Size 2022 | USD 1.5billion |
Market Size 2023 | USD 1.69billion |
Market Size 2030 | USD 3.59 billion |
Compound Annual Growth Rate (CAGR) | 13.30% (2022-2030) |
Base Year | 2021 |
Market Forecast Period | 2022-2030 |
Historical Data | 2018 & 2020 |
Market Forecast Units | Value (USD Billion) |
Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Type, Treatment, End User and Region |
Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
Countries Covered | The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
Key Companies Profiled | Johnson & Johnson Services Inc, Abbott, Medtronic Plc, Boston Scientific Corporation, MicroPort Scientific Corporation, Biotronik SE & Co. KG, Koninklijke Philips N.V., AtriCure Inc., CardioFocus, Osypka AG and others |
Key Market Opportunities | Rising technological advancement in atrial fibrillation tolls and technology |
Key Market Dynamics | Rising prevalence of atrial fibrillation Increasing approval of products |
The global atrial fibrillation market size was valued at USD 1.5 Billion in 2022.
The global market is projected to grow at a CAGR of 13.30% during the forecast period, 2023-2030.
North America had the largest share in the global market
The key players in the market are Johnson & Johnson Services Inc, Abbott, Medtronic Plc, Boston Scientific Corporation, MicroPort Scientific Corporation, Biotronik SE & Co. KG, Koninklijke Philips N.V., AtriCure Inc., CardioFocus, Osypka AG, and others.
The Surgical procedures category dominated the market in 2022.
The Hospitals had the largest share in the global market.